Summary:
Arizona Research Center is conducting a Phase 3, Randomized, Double Blind, Placebo and Active-Controlled, Multicenter, Parallel-Group Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain.
Qualified Participants Must:
• Be 18 years of age or older
•
Have had Chronic Low Back pain for at least 3 months
•
Have documented history of previous inadequate treatment response to at least 3 different categories of agents (e.g. Acetaminophen, Prescription NSAIDs, Opioids, etc.)
•
*More inclusion and exclusion criteria apply